Peptide Therapeutics intermediate
ATSP-7041 - First-in-Human (NCT02264614)
First-in-human trial of ATSP-7041, a stapled peptide MDM2 antagonist. This peptide or oligopeptide is studied for its biological activity, structure-activity...
By Encyclopeptide Editorial | 1 min read
atsp-7041-first-in-human-nct02264614 peptide research
Overview
First-in-human trial of ATSP-7041, a stapled peptide MDM2 antagonist.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “ATSP-7041 - First-in-Human (NCT02264614)” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about ATSP-7041 - First-in-Human (NCT02264614) with interactive quizzes on Wikipept.
Take a Quiz on Wikipept